Home › Bladder Cancer › Idaho › Boise
Bladder Cancer clinical trials in Boise, ID
4 studies for Bladder Cancer are looking for participants at sites in and around Boise (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- St. Luke's Cancer Institute: Boise, Boise
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Boise
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY34 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Washington, DC26 studies
- Boston, MA26 studies
- Los Angeles, CA24 studies
- Baltimore, MD24 studies
- St. Louis, MO22 studies
- Edison, NJ22 studies
- Philadelphia, PA21 studies
- Chicago, IL21 studies
Other studies in Boise
- Non-Small Cell Lung Cancer14 studies
- Lung Cancer11 studies
- Prostate Cancer9 studies
- Acute Myeloid Leukemia8 studies
- Colorectal Cancer7 studies
- Colon Cancer7 studies
- Breast Cancer6 studies
- Melanoma6 studies
- Respiratory Distress Syndrome6 studies
- Burkitt Lymphoma5 studies
- Pancreatic Cancer4 studies
- Chronic Lymphocytic Leukemia4 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.